Effect of a single autologous cord blood infusion on beta‐cell and immune function in children with new onset type 1 diabetes: a non‐randomized, controlled trial. Issue 2 (19th September 2013)

• Record Type: Journal Article
• Authors: Giannopoulou, Eleni Z; Puff, Ramona; Beyerlein, Andreas; von Luettichau, Irene; Boerschmann, Heike; Schatz, Desmond; Atkinson, Mark; Haller, Michael J; Egger, Dietmar; Burdach, Stefan; Ziegler, Anette‐Gabriele
• Is Part Of: Pediatric diabetes. Volume 15:Issue 2(2014:Mar.)
• Page Start: 100
• Page End: 109
• Publication Date: 2013-09-19
• Subjects: Diabetes in children -- Periodicals; 616.462
• DOI: 10.1111/pedi.12072
• Languages: English
• ISSNs: 1399-543X

Abstract

<abstract abstract-type="main" id="pedi12072-abs-0001"> <title>Abstract</title> <sec id="pedi12072-sec-0001" sec-type="section"> <title>Background</title> <p id="pedi12072-para-0001">The application of autologous cord blood in children with type 1 diabetes has been found to be safe, but not to preserve beta‐cell function in a previous study, which, however, had not included a control group.</p> </sec> <sec id="pedi12072-sec-0002" sec-type="section"> <title>Objective</title> <p id="pedi12072-para-0002">To compare the changes of metabolic and immune function over time between cord blood infused children and natural controls.</p> </sec> <sec id="pedi12072-sec-0003" sec-type="section"> <title>Subjects and methods</title> <p id="pedi12072-para-0003">Seven children with newly diagnosed type 1 diabetes underwent a single autologous cord blood infusion and 10 children were enrolled as natural controls in a non‐randomized, controlled, open label intervention trial. Primary analyses were performed 1 year following cord blood infusion. Cases and controls were compared regarding metabolic [area under the curve (AUC) and peak C‐peptide, insulin use, and HbA1c] and immune outcome (islet autoantibody titer and T‐cell response), adjusted for age, gender, diabetes duration, and baseline levels.</p> </sec> <sec id="pedi12072-sec-0004" sec-type="section"> <title>Results</title> <p id="pedi12072-para-0004">There were no significant adverse events related to the infusion. Metabolic and immune outcomes were not significantly different at 12 months follow‐up between infused children and controls (e.g., adjusted p = 0.244 for AUC C‐peptide, adjusted p = 0.820 for insulin use, adjusted p = 0.772 for peripheral regulatory T cells). Six‐month change of AUC C‐peptide correlated significantly with the number of infused CD34+ cells (r = 0.931, p = 0.002).</p> </sec> <sec id="pedi12072-sec-0005" sec-type="section"> <title>Conclusions</title> <p id="pedi12072-para-0005">An autologous cord blood infusion does not change the natural course of metabolic and immune parameters after disease onset. However, the content of CD34+ cells in the stored blood sample might offer potential for improvement of future cell therapies.</p> </sec> </abstract>